
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
What's the average closing rate for U.S. dermatology practices? Mr. Atwood suspects it could be as low as 10 to 20 percent in some practices.